Floatz logo

14 assets in Juvenile Idiopathic Arthritis

Therapeutic assets addressing Juvenile Idiopathic Arthritis, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Alemtuzumab
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Cyclophosphamide
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Fludarabine
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Hydroxyurea
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Jnj-78436735
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (53)
Melphalan
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Moderna Covid-19 Vaccine Rna
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (53)
Monovalent [B.1.351] Cov2 Pres Dtm-As03
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (53)
Nivestim
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Thiotepa
Juvenile Idiopathic Arthritis
Paul SzabolcsP2CCC (53)
Methotrexate
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (52)
Tozinameran
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)P2CCC (50)
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Juvenile Idiopathic Arthritis
Duke UniversityP1CC (43)
bnt162b2
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)P2CC (43)